Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2022

View Archived Issues

LCDR regulates lysosomal function through stabilization of LAPTM5 and promotes cancer cell survival

CC40.8 antibody confers protection against SARS-CoV-2 infection

New curcumin derivatives show activity against non-small lung cancer

Chinese researchers divulge 5-HT2AR antagonists and/or melatonin MT1 and/or MT2 receptor agonists

Betta Pharmaceuticals discloses PD-1/PD-L1 interaction inhibitors

Discovery of KP-1, an antifibrotic peptide that ameliorates renal fibrosis in vivo

Chinese investigators identify Toll-like receptor antagonists

Apotex patents new antiviral compounds

Shaanxi Synthetic Pharmaceutical presents new thiobenzopyran compounds

Novel Hsp90/HDAC dual inhibitor shows antifungal activity against azole-resistant Candida albicans

RosVivo signs material transfer agreement with Lilly for RSVI-301 for diabetes

Researchers present in vitro data for GYS1 inhibitor MZE-001 in Pompe disease

APTA-1 shows promising biological effects in a coronavirus-induced acute lung injury model

Grant supports Emergex's development of synthetic T-cell vaccine candidate for Chikungunya virus

BioNTech and Medigene collaborate to develop TCR-based immunotherapies for cancer

NovoBiome and Inserm collaborate on intestinal organoid-on-a-chip technology

Engineered Wnt ligands repair BBB in neuro disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...